WINTON GROUP Ltd Purchases 50,677 Shares of Lantheus Holdings, Inc. $LNTH

WINTON GROUP Ltd lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 350.8% in the third quarter, Holdings Channel.com reports. The firm owned 65,125 shares of the medical equipment provider’s stock after purchasing an additional 50,677 shares during the quarter. WINTON GROUP Ltd’s holdings in Lantheus were worth $3,340,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Fox Run Management L.L.C. bought a new stake in Lantheus in the 2nd quarter worth approximately $654,000. Los Angeles Capital Management LLC grew its position in Lantheus by 63.2% during the second quarter. Los Angeles Capital Management LLC now owns 11,892 shares of the medical equipment provider’s stock valued at $973,000 after acquiring an additional 4,607 shares during the last quarter. Parkside Financial Bank & Trust grew its position in Lantheus by 20.2% during the second quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock valued at $103,000 after acquiring an additional 212 shares during the last quarter. CSM Advisors LLC purchased a new position in shares of Lantheus during the second quarter worth approximately $370,000. Finally, Boston Partners raised its stake in shares of Lantheus by 30.5% during the second quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock worth $46,432,000 after acquiring an additional 134,781 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on LNTH. Wall Street Zen raised shares of Lantheus from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Citizens Jmp lifted their target price on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research report on Tuesday, February 24th. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Truist Financial upped their price target on shares of Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Finally, Mizuho lifted their price objective on Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $82.17.

Lantheus Trading Up 4.0%

Shares of LNTH opened at $83.22 on Wednesday. The stock has a market capitalization of $5.38 billion, a P/E ratio of 24.69 and a beta of -0.11. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. The firm has a fifty day simple moving average of $69.68 and a two-hundred day simple moving average of $61.30.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, beating the consensus estimate of $1.17 by $0.50. The firm had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.